We are live on
!
Find out more
RA
Rosalind Advisors Portfolio holdings
AUM
$269M
1-Year Est. Return
103.38%
This Fund
S&P 500
This Quarter
Est. Return
+22.87%
1 Year Est. Return
+103.38%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$269M
AUM Growth
+$20.3M
(+8.2%)
Cap. Flow
-$13.3M
Cap. Flow
% of AUM
-4.93%
Top 10 Holdings %
Top 10 Hldgs %
74.04%
Holding
45
New
9
Increased
7
Reduced
11
Closed
10
Avg Time Held Equity + Options
4
quarters
Top 10 Avg Time Held Equity + Options
3.7
quarters
Top 20 Avg Time Held Equity + Options
3.5
quarters
Avg Time Held Equity only
4.8
quarters
Top 10 Avg Time Held Equity only
3.7
quarters
Top 20 Avg Time Held Equity only
3.6
quarters
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Verastem
VSTM
|
+$8.94M |
| 2 |
Abivax
ABVX
|
+$2.36M |
| 3 |
Fennec Pharmaceuticals
FENC
|
+$2.28M |
| 4 |
HELP
Helus Pharma Inc. Common Stock
HELP
|
+$2.13M |
| 5 |
Neuraxis
NRXS
|
+$1.64M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CG Oncology
CGON
|
+$6.54M |
| 2 |
Viridian Therapeutics
VRDN
|
+$4.9M |
| 3 |
Vaxcyte
PCVX
|
+$4.89M |
| 4 |
Celldex Therapeutics
CLDX
|
+$4.2M |
| 5 |
Definium Therapeutics
DFTX
|
+$2.36M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 98.9% |
| 2 | Miscellaneous | 1.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
1
Delcath Systems
DCTH
$532M
| $41.6M | 15.44% |
3,300,389
| – | – |
2023 Q4
10 quarters
|
|
|
2
Fennec Pharmaceuticals
FENC
$357M
| $34.3M | 12.73% |
3,188,001
+279,800
| +10% | +$2.28M |
2024 Q4
6 quarters
|
|
3
Xeris Biopharma Holdings
XERS
$1.86B
| $23M | 8.56% |
2,908,981
-322,719
| -10% | -$2.06M |
2023 Q4
10 quarters
|
|
4
Savara
SVRA
$982M
| $19.6M | 7.27% |
3,178,121
-25,600
| -0.8% | -$137K |
2024 Q4
6 quarters
|
|
|
5
Verastem
VSTM
$675M
| $15.2M | 5.66% |
3,986,509
+1,848,034
| +86% | +$8.94M |
2024 Q4
6 quarters
|
|
6
X4 Pharmaceuticals
XFOR
$258M
| $15M | 5.58% |
3,214,766
| – | – |
2025 Q3
3 quarters
|
|
7
EyePoint Inc
EYPT
$265M
| $14.1M | 5.25% |
988,230
-48,507
| -5% | -$649K |
2025 Q3
3 quarters
|
|
|
HELP
8
Helus Pharma Inc. Common Stock
HELP
$767M
| $12.9M | 4.8% |
1,956,814
+425,000
| +28% | +$2.13M |
2024 Q1
9 quarters
|
|
9
Vor Biopharma
VOR
$1.13B
| $11.9M | 4.44% |
648,600
-51,400
| -7% | -$778K |
2026 Q1
1 quarter
|
|
|
10
Vaxcyte
PCVX
$10.4B
| $11.6M | 4.32% |
200,000
-90,000
| -31% | -$4.89M |
2026 Q1
1 quarter
|
|
11
MediWound
MDWD
$158M
| $11M | 4.09% |
749,054
| – | – |
2023 Q4
10 quarters
|
|
|
12
Celldex Therapeutics
CLDX
$2.22B
| $7.44M | 2.76% |
200,000
-130,000
| -39% | -$4.2M |
2026 Q1
1 quarter
|
|
13
BioCryst Pharmaceuticals
BCRX
$2.06B
| $7.22M | 2.68% |
721,504
-201,553
| -22% | -$1.82M |
2026 Q1
1 quarter
|
|
14
Profound Medical
PROF
$256M
| $5.51M | 2.05% |
828,118
| – | – |
2023 Q4
10 quarters
|
|
15
Talphera
TLPH
$55.5M
| $5.32M | 1.98% |
5,169,501
+1,815,585
| +54% | +$1.55M |
2023 Q4
10 quarters
|
|
16
Atea Pharmaceuticals
AVIR
$399M
| $4.98M | 1.85% |
1,070,550
-101,305
| -9% | -$504K |
2026 Q1
1 quarter
|
|
17
Myomo
MYO
$51.1M
| $3.78M | 1.41% |
3,637,886
-209,386
| -5% | -$204K |
2023 Q4
10 quarters
|
|
18
Ovid Therapeutics
OVID
$428M
| $2.98M | 1.11% |
1,107,994
| – | – |
2026 Q1
1 quarter
|
|
|
19
Neuraxis
NRXS
$81.6M
| $2.97M | 1.1% |
508,055
+221,917
| +78% | +$1.64M |
2025 Q4
2 quarters
|
|
|
20
Abivax
ABVX
$7.52B
| $2.78M | 1.03% |
+20,869
| New | +$2.36M |
2026 Q2
0 quarters
|
|
21
InspireMD
NSPR
$23.4M
| $2.73M | 1.02% |
3,905,743
| – | – |
2023 Q4
10 quarters
|
|
22
Regentis Biomaterials
RGNT
$11.4M
| $2.48M | 0.92% |
701,685
+450,175
| +179% | +$1.28M |
2025 Q4
2 quarters
|
|
23
PUT
SELLAS Life Sciences
SLS
$2.51B
| $2.3M | 0.86% |
+568,700
| New | +$3.93M |
2026 Q2
0 quarters
|
|
24
PolyPid
PYPD
$99.1M
| $1.98M | 0.73% |
389,455
-208,471
| -35% | -$961K |
2024 Q1
9 quarters
|
|
25
Biofrontera
BFRI
$13.3M
| $1.21M | 0.45% |
1,275,609
+111,647
| +10% | +$110K |
2024 Q1
9 quarters
|
|
Similar funds
GPFA
TW
PM
ZEP
LBW
VP
5W
NF
Rosalind Advisors's Q2 2026 Portfolio in Review
As of Q2 2026, Rosalind Advisors held 45 positions worth $269M, up 8.2% from $249M the previous quarter. Its ten largest holdings account for 74% of the portfolio.
Rosalind Advisors withdrew a net $13.3M in Q2 2026, closing 10 positions and reducing 11 holdings. Its most notable exit was CG Oncology, an estimated $6.54M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Miscellaneous.
Against the trend, Rosalind Advisors opened a new position in Abivax worth $2.78M.
- Rosalind Advisors's largest Q2 2026 buy was Abivax: 20,869 shares worth $2.78M.
- Rosalind Advisors added most to Verastem in Q2 2026, an estimated $8.94M increase.
- Rosalind Advisors's biggest Q2 2026 reduction was Vaxcyte, cutting an estimated $4.89M.
- Rosalind Advisors fully exited CG Oncology in Q2 2026, selling an estimated $6.54M.
- Rosalind Advisors's ten largest holdings make up 74% of its $269M portfolio in Q2 2026.
- Rosalind Advisors opened 9 new positions and closed 10 in Q2 2026.
- Rosalind Advisors's portfolio value rose 8.2% quarter-over-quarter to $269M.
Based on Rosalind Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.